Where the stock stands
Granules India Ltd. is a Healthcare-sector listing, and the evidence pack opens with a gap in its own clock: it is dated 2026-09-14, while the last close it carries is from 2026-09-11. The price block reports a last price of ₹909.3 against a previous close of ₹909.3, a change of 0.0% — a carried-forward close, not a live tick, so the flat reading is not evidence of a quiet session.
The close sits 0.61% below the 52-week high of ₹914.85 and 78.1% above the 52-week low of ₹510.55. Trailing returns are 7.19% over a week, 6.03% over a month, 21.5% over three months and 73.1% over a year; the week's gain exceeding the month's says the advance is concentrated in a few sessions. The shares carry a price-to-earnings multiple of 33.95 and a price-to-book of 4.45 on earnings per share of 26.92, with a market capitalisation of ₹22,644 crore and a dividend yield of 0.19%.
What the smart-money flow shows
The pack lists eight institutional deals, every one stamped 2026-09-11. The sell side is two prints from a single account, KRISHNA PRASAD CHIGURUPATI, at ₹1,160 crore and ₹348.64 crore, both filed under the category 'Other' rather than an institutional class. The buy side is six counterparties: SMALLCAP WORLD FUND INC at ₹303.11 crore, BNP PARIBAS FINANCIAL MARKETS at ₹115 crore and GOLDMAN SACHS BANK EUROPE SE at ₹102.42 crore — the two tagged FII, meaning foreign institutional investor — plus KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITED at ₹100.71 crore under Insurance, CLARUS CAPITAL 1 at ₹75 crore and MYRAA VARUN RAHEJA at ₹60 crore.
Two cautions belong with that list. Block tape often shows intermediaries on both sides of a print, so a bank listed as a buyer is not by itself conviction. And the pack's own news list carries an NDTV Profit headline reporting a promoter preparing to offload a stake of roughly Rs 1,500 crore at a fixed floor price. If the two sells are that transaction, the six buys are a placement being absorbed rather than independent accumulation — but the pack does not link the records to the headline, so this stays a possibility. On the rest, the data is silent: no F&O positioning block, no insider-filing record, no institutional streak. Those fields are absent altogether rather than present and empty.
The technical picture
Relative volume reads 9.08 — roughly nine times usual volume — which cannot describe the same session as the 0.0% price change. The volume figure belongs to the 2026-09-11 tape that carried the block deals; the unchanged price is the stale carry-forward. The conflict is in the pack, not in the reading of it.
RSI(14), a 14-day momentum oscillator, stands at 66.8: elevated, but short of the conventional overbought line. The close is above both the 50-day and 200-day moving averages, and the pack flags neither a golden cross nor a death cross, so the longer trend is intact with no fresh crossover to date it. A univest.in headline also describes a fresh 52-week high at Rs 909.65, while the pack's own 52-week high field is ₹914.85; nothing here resolves which is right.
Catalysts and what to watch
The catalyst block holds six entries identical in wording: a report that a Granules India subsidiary received FDA approval for an ADHD drug addressing a $41M market, tagged bullish and re-dated on each day from 2026-09-09 through 2026-09-14. That is one story carried forward six times, not six approvals, and the count should not be read as thickening news flow. Elsewhere, scanx.trade reported 61 days ago on the FY 2025-26 annual report and revenue crossing a ₹50,000 Mn milestone.
What the data establishes is narrow: a stock within 0.61% of its 52-week high after a year in which it gained 73.1%, one very large seller against six buyers on a single day, and one approval headline repeated through the week. What it does not establish is a single driver for the move. No F&O record and no insider filing corroborate the deal tape, the volume and price fields describe different sessions, and nothing here dates the approval report against the block prints.